DCM
KRTX

Dupont Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Dupont Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-429
Closed -$96K – 1551
2022
Q3 		$96K Buy
+429
New +$86.8K 0.01% 1058

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dupont Capital Management's KRTX Position: Q4 2022 in Review

Dupont Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2022, closing a stake of 429 shares — an estimated $96K sold.

Dupont Capital Management first reported a position in KRTX in Q3 2022 and held it in 1 quarter. The position peaked at $96K in Q3 2022. 248 funds tracked by Wall St. Rank hold KRTX as of Q4 2022.

  • Dupont Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Dupont Capital Management sold 429 Karuna Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $96K.
  • Dupont Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Dupont Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $96K in Q3 2022.
  • 248 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Dupont Capital Management's 13F filing for Q4 2022, filed 26 Jan 2023.